Acumen Pharmaceuticals, Inc.
NMS: ABOSLive Quote
About Acumen Pharmaceuticals, Inc.
Healthcare
Biotechnology
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
📊 Fundamental Analysis
Acumen Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -96.2%, which indicates that capital utilization is currently under pressure.
At a current price of $2.47, ABOS currently sits at the 59th percentile of its 52-week range (Range: $0.85 - $3.60).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$158.18M
Trailing P/E
--
Forward P/E
-1.77
Beta (5Y)
0.34
52W High
$3.60
52W Low
$0.85
Avg Volume
893K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App